BiotechTube

Cimzia + Mesalamine

ApprovedTerminated
2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

Feb 1, 2013 → Jun 1, 2016

NCT ID
NCT01696942

About Cimzia + Mesalamine

Cimzia + Mesalamine is a approved stage product being developed by UCB for Crohn's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01696942. Target conditions include Crohn's Disease.

What happened to similar drugs?

8 of 20 similar drugs in Crohn's Disease were approved

Approved (8) Terminated (3) Active (12)
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Infliximab + Prednisolone + AzathioprinePfizerApproved
✅Celebrex + placeboPfizerApproved
✅Certolizumab PegolUCBApproved
✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved
✅natalizumabBiogenApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01696942ApprovedTerminated

Competing Products

20 competing products in Crohn's Disease

See all competitors
ProductCompanyStageHype Score
CT-P13 + RemicadeCelltrionPhase 3
40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
CP-461Astellas PharmaPhase 2
35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumab + adalimumab + placeboEisaiPhase 2/3
38
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35
MirikizumabEli LillyPhase 3
44
Matching Placebo for Upadacitinib + UpadacitinibAbbViePhase 3
40
Adalimumab + PlaceboAbbViePhase 3
40
Upadacitinib + Placebo for UpadacitinibAbbViePhase 3
40
Placebo + ABT-494AbbViePhase 2
35
ABT-494AbbViePhase 2
35
Risankizumab + ComparatorAbbViePre-clinical
33